Methods and kits for predicting the risk of having a cardiovascular event in a subject
AssigneeUniversite Paris Descartes
InventorsZiad Mallat, Alain Tedgui, Tabassome Simon, Nicolas Danchin
Life of this patent
Estimating the term…
Abstract
The present invention relates to in vitro methods and kits for predicting the risk of having a cardiovascular event in a subject. More particularly, the invention relates to an in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the step of measuring the level of IL-17 in a blood sample obtained from said subject.
Claims12
An in vitro method for predicting the risk of a cardiovascular event in a subject, said method comprising the steps of
- i) measuring a level of IL-17 in a blood sample obtained from said subject by
- contacting the blood sample with a binding partner that is specific for the IL-17, wherein the step of contacting forms an IL-17-binding partner complex, and
- detecting the IL-17-binding partner complex as a measure of the level of IL-17;
- and
- ii) comparing the level measured at step i) with a reference value, wherein a difference between said IL-17 level and said reference value is indicative of a risk of having a cardiovascular event.
A method for treating a subject at risk of a cardiovascular event, comprising the steps of:
- analyzing a blood sample obtained from said subject by
- contacting the blood sample with a binding partner that is specific for the IL-17, wherein the step of contacting forms an IL-17-binding partner complex,
- detecting the IL-17-binding partner complex as a measure of a level of IL-17;
- and
- comparing the level measured in said detecting step with a reference value, and
- when a difference between said IL-17 level and said reference value is indicative of said risk of having said cardiovascular event, selecting a treatment regimen for said subject.
A method for monitoring effectiveness of a treatment for a subject at risk of a cardiovascular event, comprising the steps of:
- analyzing blood samples obtained from said subject before and after receiving said treatment by
- contacting the blood sample with a binding partner that is specific for the IL-17, wherein the step of contacting forms an IL-17-binding partner complex,
- detecting the IL-17-binding partner complex as a measure of a level of IL-17;
- and
- comparing the level measured in said detecting step with a reference value, and
- determining effectiveness of said treatment based on differences between a comparison made for a first blood sample before said treatment and a comparison made for a second blood sample after said treatment.
Dependencies are inferred from the claim text.